|
|
|
| Safety evaluation of Iodixanol Injection in CT injection of cardiovascular system |
| WANG Xiaoyan XIAO Jiwei WAN Yulei |
| Department of CT Chamber, Wuhan NO.6 Hospital, Hubei Province, Wuhan 430000, China |
|
|
|
Abstract Objective To investigate the effect and safety of Iodixanol Injection in CT injection of cardiovascular system. Methods A total of 385 patients with cardiovascular system disease from January 2017 to March 2018 were enrolled in Wuhan NO.6 Hospital. The patients were numbered according to the order of admission and were randomly divided into the control group (n = 192) and the study group (n = 193) by random number table method. CT angiography was performed in both groups, and Iohexol Injection was used as CT contrast agent in the control group. Iodoxacin Injection was used as CT contrast agent in the study group. The angiographic effects，pre- and post-contrast renal function indicators, including serum creatinine (Scr), urinary protein excretion rate (UAER), blood urea nitrogen (BUN), and adverse reactions, adverse reactions including hypotension, shock, vomiting, nausea and facial edema were compared between the two groups. Results The excellent rate of angiography in the study group was higher than that in the control group, but the difference between the two groups was not statistically significant (P > 0.05). There was no significant difference in serum Scr, UAER and BUN levels between the two groups before angiography (P > 0.05). The levels of serum Scr, UAER and BUN in the two groups were higher than those in the control group (P < 0.05). The incidence of adverse reactions in the study group was lower than that in the control group (P < 0.05). Conclusion Using Ioxanol Injection as contrast agent in CT injection angiography of patients with cardiovascular diseases can achieve good contrast effect, and is conducive to alleviating kidney injury. The incidence of adverse reactions is low and has high safety.
|
|
|
|
|
|
[1] 师俊芳，侯铮.不同造影剂注射方式在128层螺旋CT冠状动脉血管造影中的比较[J].河北医药，2012，34（17）：2636-2637.
[2] Sun Z，Cao Y. Multislice CT angiography assessment of left coronary artery：correlation between bifurcation angle and dimensions and development of coronary artery disease [J]. Eur J Radiol，2011，79（2）：e90-e95.
[3] 郑超，刘惠敏，刘志鹏，等.冠状动脉造影术中造影剂个性化注射法的应用[J].中国基层医药，2015，22（23）：3524-3526.
[4] Franke RP，Scharnweber T，Fuhrmann R，et al. Effect of radiographic contrast media （Iodixanol，Iopromide） on the spectrin/actin-network of the membranous cytoskeleton of erythrocytes [J]. Clin Hemorheol Microcirc，2013，54（3）：273-285.
[5] 王子真，吴新淮，韩威，等.低浓度造影剂在双能谱CT冠状动脉造影的可行性研究[J].中国医学装备，2016，13（5）：41-44.
[6] 曹丽珍，杜祥颖，卢洁，等.CT冠状动脉成像中造影剂注射技术的研究进展[J].中华老年心脑血管病杂志，2013， 15（2）：216-217.
[7] Franke RP，Fuhrmann R，Mrowietz C，et al. Do radiographic contrast media （Iodixanol or Iomeprol） induce a perturbation of human arterial and/or venous endothial cells in vitro on extracellular matrix [J]. Clin Hemorheol Microcirc，2012，50（1/2）：49.
[8] 孙燕，方芳，付培德，等.CT检查中造影剂不良反应的预防、处理及对影像学检查的影响分析[J].现代生物医学进展，2014，14（4）：755-758.
[9] 耿巍，张瑶，田祥，等.冠状动脉CT血管造影检查后短时间内行冠状动脉介入诊疗的安全性研究[J].河北医科大学学报，2017，38（3）：266-269.
[10] Wang YC，Tang A，Chang D，et al. Significant perturbation in renal functional magnetic resonance imaging parameters and contrast retention for iodixanol compared with iopromide：an experimental study using blood-oxygen-level-dependent/diffusion-weighted magnetic resonance imaging and comp [J]. Invest Radiol，2014，49（11）：699-706.
[11] 陈琼花.造影剂在CT增强中运用体会[J].海峡药学，2014，26（12）：169-170.
[12] 蔡然，刘晓蒙.碘克沙醇致造影剂肾病[J].药物不良反应杂志，2013，15（2）：93-94.
[13] 王鸿林，姚伟根，黄国来，等.CT增强静脉注射碘帕醇与碘克沙醇对患者肾功能的影响[J].海峡药学，2012， 24（4）：149-150.
[14] Ronda N，Potì F，Palmisano A，et al. Effects of the radiocontrast agent iodixanol on endothelial cell morphology and function [J]. Vascul Pharmacol，2013，58（1/2）：39-47.
[15] 王朝霞，张月英.心脏冠状动脉血管成像中造影剂使用的研究进展[J].中国药物与临床，2013，13（11）：1442-1444.
[16] Christensen JD，Meyer LT，Hurwitz LM，et al. Effects of iopamidol-370 versus iodixanol-320 on coronary contrast， branch depiction， and heart rate variability in dual-source coronary MDCT angiography [J]. AJR Am J Roe-ntgenol，2011，197（3）：445-451.
[17] 田美云，张月英.碘海醇与碘克沙醇对增强CT检查患者肾功能影响的对比研究[J].中国医药，2017，12（3）：378-381.
[18] 刘振良，高全清，贾国渠，等.国产碘克沙醇在心血管高危人群冠脉造影和介入治疗的安全性观察[J].介入放射学杂志，2015，24（2）：106-109.
[19] 邓增潮，陈华栋，梁增杰，等.碘克沙醇在高危患者造影中的安全性[J].中国医院用药评价与分析，2013，13（4）：368-370.
[20] 王达，严静雯.碘普罗胺注射液和碘克沙醇注射液在数字减影血管造影中的应用分析[J].中国处方药，2014， 12（10）：87.
[21] 药素毓，王亚痴，张钲.造影剂碘克沙醇在冠状动脉造影中的临床观察[J].卫生职业教育，2016，34（22）：150-151.
[22] 宋福春.碘克沙醇与碘海醇对接受冠脉造影及介入治疗患者肾功能影响的比较[J].实用医药杂志，2014，31（2）：99-101.
[23] 刘君，聂大奥，靳文.国内外碘克沙醇在心血管高危人群冠脉造影和介入治疗的有效性和安全性比较[J].广州医学院学报，2016，44（3）：45-47.
[24] Meurer K，Laniado M，Hosten N，et al. Intra-arterial and intravenous applications of Iosimenol 340 injection， a new non-ionic，dimeric，iso-osmolar radiographic contrast medium：phase 2 experience [J]. Acta Radiol，2015， 56（6）：702-708. |
|
|
|
